Transcript SGLT2 Inhibitors as Add-On for Poorly Controlled Patients on DPP

Supporting the Rationale for the Use of
Dapagliflozin as an Add-on to Poorly
Controlled Patients on Saxagliptin and
Metformin
Zachary Bloomgarden, MD
Clinical Professor
Division of Endocrinolog
Icahan School of Medicine
New York, New York
Julio Rosenstock, MD
Clinical Professor
University of Texas
Southwestern Medical School
Dallas, TX
American Diabetes Association 2014, Meeting
Conclusions
• Newer anti-diabetes agents have come to be more likely prescribed by
practitioners as they grapple for solutions to the growing diabetes
epidemic.
• Leading researchers agree that metformin should be the beginning
choice for all type two patients, but after that the field is wide open
• Many prescribers try to mix and match because of formulary guidelines
and cost consciousness.
• Adding on supposedly synergistic medications often leave the patient
with less than meaningful response than is expected
• The Use of SGLT-2 Inhibitors Blockers with DPP-4 Inhibitors has been
shown to have a positive effect on A1c, Weight Loss, and Hypertension